CYCLERION THERAPEUTICS INC (CYCN)
US23255M2044 - Common Stock
Top movers in Friday's after hours session
After hours stock analysis on 2024-11-15: top gainers and losers in today's session.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors of Cyclerion....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024
Cyclerion Therapeutics just reported results for the first quarter of 2024.
CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023
Cyclerion Therapeutics just reported results for the fourth quarter of 2023.
CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclerion Therapeutics (NASDAQ:CYCN) just reported results for the fourth quart...
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep...
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in...
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it...
Cyclerion announces 1 for 20 reverse stock split (NASDAQ:CYCN)
Cyclerion Therapeutics (CYCN) announced a reverse stock split of its outstanding common shares at a ratio of 1-for-20, effective as of 5:00 p.m
Cyclerion Announces Reverse Stock Split
Cyclerion Announces Reverse Stock Split
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN)...
Cyclerion Therapeutics down 6% on spin off agreement (NASDAQ:CYCN)
Cyclerion Therapeutics (CYCN) enter agreement to sell two of its sGC stimulator assets in exchange for cash and equity ownership to a new private company
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction ...
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash...